Page 3 - Natco Pharma

Natco Pharma Q3 net up 11% at Rs 2.17 billion

However, the revenues declined by 16% to Rs 5.74 bn

Natco a safer bet in volatile pharma pack

US sales are being driven by niche complex products, domestic specialty range is also seeing traction

Natco Pharma extends gain after QIP launch

The stock rallied 5% to Rs 1,013 on the BSE in intra-day trade, up 9% in past four trading sessions as compared to 0.57% decline in the S&P BSE Sensex.

Natco Pharma up 20% as Mylan gets USFDA nod for generic Glatiramer Acetate

The stock up 20% to Rs 954 on BSE after the company said its marketing partner Mylan receives final approval of generic Glatiramer Acetate, for both 20 mg/mL and 40 mg/mL versions.

Natco Pharma's niche portfolio an opportunity

The stock price correction can be considered as a good opportunity for long-term investors

Natco's niche portfolio is an opportunity

The company's strong prospects make the risk-reward favourable

Natco Pharma dips 12% in two days post Q1 results on profit booking

Thus far in 2017, the stock had gained 65% against 6% fall in healthcare index till Monday.

Natco Pharma Q1 net doubles to Rs 94 cr on rise in formulation sales

Company board recommends interim dividend of Rs 1.25 a equity share of Rs 2 each

Natco Pharma receives FDA inspection report on Kothur formulations facility

EIR is given when the unit meets the expectations of the US drug regulator on CGMP regulations

Natco stands out with its niche portfolio

Complex product pipeline for US and specialty focus in domestic biz will drive growth for many years

Natco Pharma hits new high; up 80% in 2017

The stock hit a new high of Rs 1,054, up 3%, extending its 15% gain in past eight trading sessions.

Natco Pharma launches generic hepatitis C drug in India

The company's product is generic version of Gilead Sciences Inc's Epclusa tablets

Multiple growth pills should keep Natco Pharma's revenue charts healthy

The Natco Pharma stock was up six per cent in two trading sessions on expectations of a strong March quarter performance and near-term triggers such as approval for generics of multiple sclerosis drug Copaxone. For the March quarter, while the pharma sector is expected to report single-digit revenue and flat net profit growth, Natco Pharma could witness a growth of 24 per cent in revenues and 117 per cent rise in its bottom line. The better performance is due to the launch of the generic version of influenza drug Tamiflu in December 2016 in the US. The drug, marketed by its US partner Alvogen, has sales of about $400 million. In addition to a strong March quarter performance, the next trigger is the approval for generics of Copaxone (40 mg strength) which has annual sales of $3.3 billion. The verdict on a patent case is due in May 2017 and a favourable outcome of this could mean a ~400-500-crore revenue opportunity, according to analysts. Natco, along with its US partner Mylan, ...

Natco Pharma gets USFDA approval for leukemia drug

Natco plans to launch this on November 1, 2019 through its partner Breckenridge Pharmaceutical Inc

Natco Pharma gains on USFDA nod for generic Bendamustine HCL powder

The stock moved higher by 6% to Rs 632 on the BSE in intra-day trade

Natco gets USFDA nod for anti-sleep tablets

Armodafinil treats daytime sleepiness linked to sleep apnea, narcolepsy and shift work disorder; generic equivalent in the US had sales of $480 mn in 2015

Natco plans to double drug filings next year

The company aims to file six abbreviated new drug applications (ANDA) during current financial year

Maylan gets favourable ruling on one more patent of Copaxone

The company, which is Natco Pharma's marketing partner, hopes to translate this potential para-4 filing into a product launch after clearing legal hurdles

Natco Pharma upbeat over US Patent Office's ruling on two of Copaxone patents

In August 2014, Mylan had filed the abbreviated new drug application for multiple sclerosis drug Copaxone 40 mg/ml with the US FDA

Natco Pharma zooms on EIR for Chennai facility

The stock moved higher to its fresh lifetime high of Rs 703, up 7% on the National Stock Exchange.